Imugene's unique platform technologies aim to harness the body's immune system against tumors, potentially achieving similar or greater effects than synthetic monoclonal antibodies and other immunotherapies. Their product pipeline includes B-cell vaccine candidates and an oncolytic virotherapy for various cancers. The company is supported by a team of international cancer experts and is focused on developing new cancer therapies for global markets.